Valuation: Brooks Laboratories Limited

Market Cap 176.74Cr 1.85Cr 1.58Cr 1.48Cr 1.36Cr 2.54Cr 2.58Cr 17Cr 6.82Cr 89Cr 6.94Cr 6.79Cr 293.67Cr P/E 2025
-28.6x
P/E 2026 4.45x
Enterprise Value 178.59Cr 1.87Cr 1.6Cr 1.5Cr 1.37Cr 2.57Cr 2.6Cr 18Cr 6.89Cr 90Cr 7.01Cr 6.86Cr 296.73Cr EV / Sales 2025
3.93x
EV / Sales 2026 1.3x
Free-Float
44.12%
Yield 2025 *
-
Yield 2026 -
13/08 Brooks Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
17/07 Brooks Laboratories Limited Announces Appointment of Rajesh Mahajan to President Trading and Senior Management Personnel, Effective July 17, 2026 CI
19/06 Steriscience Specialties Private Limited agreed to acquire an additional 16.33% stake in Brooks Steriscience Limited from Brooks Laboratories Limited for INR 1.1 billion. CI
29/05 Brooks Laboratories appoints Prashant Rathi as CEO RE
29/05 Brooks Laboratories names Prashant Rathi as CEO RE
29/05 Brooks Laboratories Limited Announces Appointment of Prashant Rathi as Chief Executive Officer, Effective June 1, 2026 CI
29/05 Brooks Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
06/02 Brooks Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
16/25/16 Brooks Laboratories Limited Announces That Mr. Rajesh Mahajan Resigned as President - Procurement, with Effect from 16 October 2025 CI
13/25/13 Brooks Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
28/25/28 Brooks Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2025 CI
13/25/13 Brooks Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
26/24/26 Brooks Laboratories Limited Appoints Ms. Krutika Mohan Rane as Company Secretary & Compliance Officer, Effective 26 December 2024 CI
1 day+4.18%
1 week-1.54%
Current month+1.44%
1 month-7.31%
3 months+20.09%
6 months-16.77%
Current year-22.89%
1 week 58.26
Extreme 58.26
62.41
1 month 58.1
Extreme 58.1
67.95
Current year 36.9
Extreme 36.9
82.3
1 year 36.9
Extreme 36.9
162.8
3 years 36.9
Extreme 36.9
202.8
5 years 36.9
Extreme 36.9
202.8
10 years 14.05
Extreme 14.05
202.8
Manager TitleAgeSince
Chief Executive Officer - 01/06/2026
Chief Executive Officer 58 23/01/2002
President 57 23/08/2023
Director TitleAgeSince
Director/Board Member 62 10/09/2010
Director/Board Member 60 13/09/2011
Director/Board Member 53 23/11/2022
Change 5-day change 1-year change 3-year change Capi.($)
+4.18%-1.54% - - 1.85Cr
-0.08%-1.43%+15.99%+67.26% 4.77TCr
-3.21%+1.37%+52.36%+125.75% 4.03TCr
-0.40%-1.23%-10.08%+16.08% 1.21TCr
+1.11%-1.34%+13.61%+71.49% 1.17TCr
0.00%+0.58%+30.65%+148.80% 918.98Cr
-0.39%-0.92%+19.81%+39.54% 757.14Cr
-1.35%+0.74%+47.03%-11.93% 723.59Cr
-0.64%-0.02%+19.42%+199.06% 683.65Cr
-5.36%-6.36%-36.28%+18.28% 541.95Cr
Average -0.61%-1.11%+16.95%+74.93% 1.64TCr
Weighted average by Cap. -1.16%-0.57%+24.44%+83.40%

Financials

2025 2026
Net sales 83Cr 86.29L 73.91L 69.16L 63.31L 1.19Cr 1.2Cr 8.17Cr 3.19Cr 41Cr 3.24Cr 3.17Cr 137.17Cr 86Cr 89.61L 76.76L 71.82L 65.75L 1.23Cr 1.25Cr 8.49Cr 3.31Cr 43Cr 3.36Cr 3.29Cr 142.46Cr
Net income -9.97Cr -10.42L -9L -8L -8L -14.34L -14.53L -98.64L -38.47L -5.01Cr -39.12L -38.26L -17Cr 25Cr 25.69L 22.01L 20.59L 18.85L 35.38L 35.85L 2.43Cr 94.88L 12Cr 96.48L 94.38L 41Cr
Net Debt 7.54Cr 8L 7L 6L 6L 10.85L 10.99L 74.62L 29.1L 3.79Cr 29.59L 28.94L 13Cr 1.84Cr 2L 2L 2L 1L 3L 3L 18.25L 7L 92.62L 7L 7L 3.06Cr
Logo Brooks Laboratories Limited
Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company working on a contract basis. The Company’s segment is Pharmaceutical products, including ingredients and intermediaries. It manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup, and eye/ear drops. Its products under the Carbapenem category are Imipenem 250 (Milligram) mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, and Doripenem 500mg. It offers Penicillins in the form of injections, tablets, and dry syrup. Its general category of products includes liquid injections, dry powder injections and eye/ear drops. Its liquid injections include Iron sucrose 100mg/5ml, Iron sucrose 50mg/2.5ml, Phenytoin sodium 50mg/ml and others. Its dry powder injections include Artesunate 60mg, Artesunate 120mg, Omeprazole 40mg, Rabeprazole 20mg, Pantoprazole 40mg and others.
Employees
347
Date Price Change Volume
21/26/21 ₹61.88 +4.18% 255
20/26/20 ₹59.40 -0.17% 1,182
19/26/19 ₹59.50 +0.29% 60
18/26/18 ₹59.33 -2.34% 1,583
17/26/17 ₹60.75 -3.34% 577